Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-16-095331
Filing Date
2016-04-20
Accepted
2016-04-20 17:12:19
Documents
16
Period of Report
2016-06-09
Effectiveness Date
2016-04-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A v437325_def14a.htm DEF 14A 1144433
2 GRAPHIC line.gif GRAPHIC 43
3 GRAPHIC logo_novavax-today.jpg GRAPHIC 58252
4 GRAPHIC logo_novavax.jpg GRAPHIC 39085
5 GRAPHIC photo_gailk-boudreaux.jpg GRAPHIC 35951
6 GRAPHIC photo_garyc-evans.jpg GRAPHIC 33406
7 GRAPHIC photo_jamesf-young.jpg GRAPHIC 29722
8 GRAPHIC photo_michaela-mcmanus.jpg GRAPHIC 29642
9 GRAPHIC photo_rajivi-modi.jpg GRAPHIC 34144
10 GRAPHIC photo_richardh-douglas.jpg GRAPHIC 30558
11 GRAPHIC photo_stanleyc-erck.jpg GRAPHIC 26726
12 GRAPHIC sig_john-herrmann3.jpg GRAPHIC 14491
13 GRAPHIC sig_stanley-erck.jpg GRAPHIC 20134
14 GRAPHIC spacer.gif GRAPHIC 43
15 GRAPHIC v437325_proxycard-1.jpg GRAPHIC 1025841
16 GRAPHIC v437325_proxycard-2.jpg GRAPHIC 702099
  Complete submission text file 0001144204-16-095331.txt   4011376
Mailing Address 20 FIRSTFIELD ROAD GAITHERSBURG MD 20878
Business Address 20 FIRSTFIELD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-26770 | Film No.: 161581948
SIC: 2836 Biological Products, (No Diagnostic Substances)